PRFX - PAINREFORM LTD.

2.49
-0.070   -2.811%

Share volume: 12,090
Last Updated: 04-22-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.18%

PREVIOUS CLOSE
CHG
CHG%
$2.56
-0.07
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-5.68%
1 Month
9.21%
3 Months
217.68%
6 Months
97.62%
1 Year
8.26%
2 Year
179.84%
Key data
Stock price
$2.49
P/E Ratio 
0.00
DAY RANGE
$2.46 - $2.54
EPS 
N/A
52 WEEK RANGE
$0.58 - $3.71
52 WEEK CHANGE
$7.33
MARKET CAP 
1.567 M
YIELD 
N/A
SHARES OUTSTANDING 
7.026 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$25,194
AVERAGE 30 VOLUME 
$1,398,189
Company detail
CEO: Ilan Hadar
Region: US
Website: painreform.com
Employees: 4
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PainReform Ltd. engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair.

Recent news